Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Section 2 of 6

Executive summary

13 evidence topics · 74 sources

Clinical benefits of Lorundrostat

Burden of hypertension

Summary: definitions, prevalence, and blood pressure control

The 2025 AHA/ACC guideline sets a blood pressure treatment goal of <130/80 mm Hg for all adults and defines resistant hypertension as blood pressure above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses, or blood pressure at goal on ≥4 medications. In NHANES data from August 2021 to August 2023, the prevalence of hypertension among US adults was 47.7%. Among adults with hypertension, 51.2% were taking medication to lower blood pressure and 20.7% had blood pressure controlled to less than 130/80 mm Hg, compared with 22.2% in 2017 to March 2020, a change that was not significant. ICER states that “more than 70% of adults with hypertension have not reached their goal blood pressure”. The US Million Hearts hypertension cascade estimates that 33.2 million adults already treated with antihypertensive medication may need a dose increase or additional medications to achieve blood pressure control, and that 18.8 million of this group have blood pressure ≥140/90 mm Hg.

Estimates of resistant hypertension vary with the definition, the blood pressure goal, and the data source. Under the <130/80 mm Hg goal, the 2025 AHA/ACC guideline estimates the prevalence of resistant hypertension at approximately 8.5% to 20% among hypertensive US adults. In NHANES data from 2003 to 2020, 1,939 of 24,579 adults with hypertension had apparent treatment-resistant hypertension, a prevalence of 6.41% (95% CI 5.97% to 6.88%) corresponding to a weighted total of 6,989,821 US adults; among adults on treatment, the prevalence decreased from 17.7% to 12.6% over the study period. ICER states that almost seven million Americans are estimated to have apparent treatment-resistant hypertension. In one cohort study, resistant hypertension was identified in 60,327 (12.8%) individuals with hypertension; uncontrolled resistant hypertension accounted for 61.7% of the resistant hypertension population and 7.9% of all hypertensive individuals. A poster hosted by the manufacturer, based on Optum Market Clarity data, estimated the prevalence of uncontrolled and resistant hypertension among adults with hypertension at 27.6% and 9.8%, respectively. Among 205,750 individuals with incident hypertension started on treatment, 1.9% developed resistant hypertension within a median 1.5 years (0.7 cases per 100 person-years). Worldwide, an estimated 1.4 billion adults aged 30 to 79 years had hypertension in 2024, and approximately 320 million (23%) had it under control.

Part of apparent resistance is pseudoresistance. A clinically significant white-coat effect may be present in 28% to 39% of individuals with apparent treatment-resistant hypertension by office measurement, and in a database in which 8295 individuals had resistant hypertension, 37.5% had white-coat resistance after ambulatory blood pressure monitoring. The 2025 AHA/ACC guideline states that primary aldosteronism occurs in 5% to 10% of patients with hypertension and 20% of patients with resistant hypertension. The manufacturer states that dysregulated aldosterone is a key factor in uncontrolled or resistant hypertension in approximately 30% of patients.

Summary: morbidity and mortality

In 2024, high blood pressure was a primary or contributing cause of 680,179 deaths in the United States. The US age-adjusted death rate attributable primarily to high blood pressure was 31.5 per 100,000 in 2022 and increased 63.2% from 2012 to 2022. In a pooled analysis of one million adults in 61 prospective studies, each 20 mm Hg difference in usual systolic blood pressure at ages 40 to 69 years was associated with more than a twofold difference in the stroke death rate and twofold differences in the death rates from ischemic heart disease and other vascular causes. In an individual participant data meta-analysis of 48 randomized trials, a 5 mm Hg reduction in systolic blood pressure reduced the risk of major cardiovascular events by about 10%; in a trial-level meta-analysis of 123 studies with 613,815 participants, each 10 mm Hg reduction in systolic blood pressure was associated with a 13% reduction in all-cause mortality.

The 2025 AHA/ACC guideline states that patients with resistant hypertension have “at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death” than adults with hypertension without resistance to treatment. Among 470,386 individuals with resistant or nonresistant hypertension, resistant hypertension compared with nonresistant hypertension had adjusted hazard ratios of 1.32 for end-stage renal disease, 1.24 for ischemic heart events, 1.46 for congestive heart failure, 1.14 for cerebrovascular accident, and 1.06 for all-cause mortality, and the risks of end-stage renal disease and cerebrovascular accident were 25% and 23% greater in uncontrolled than in controlled resistant hypertension. Among patients with incident treated hypertension followed for a median 3.8 years, cardiovascular events occurred in 18.0% of those with resistant hypertension and 13.5% of those without it (adjusted HR 1.47, 95% CI 1.33 to 1.62). In another study, resistant hypertension confirmed by ambulatory blood pressure monitoring was associated with higher all-cause mortality (HR 1.36) and cardiovascular mortality (HR 1.56) than controlled hypertension. In the REGARDS study, uncontrolled resistant hypertension was associated with a 2-fold increased risk of coronary heart disease compared with controlled resistant hypertension. The manufacturer states that hypertension persisting despite two or more medications carries 1.8 and 2.5 times greater mortality risk due to cardiovascular disease or stroke, respectively.

In a meta-analysis of 31 studies including 3838 participants with primary aldosteronism and 9284 participants with essential hypertension, primary aldosteronism was associated with an increased risk of stroke (OR 2.58), coronary artery disease (OR 1.77), atrial fibrillation (OR 3.52), and heart failure (OR 2.05).

Summary: humanistic and economic burden and limitations of current treatment

In pooled US Medical Expenditure Panel Survey data from 2000 to 2011, 2501 adults with hypertension (4.4%) met criteria for apparent treatment-resistant hypertension. Compared with non-resistant hypertension, they had lower mean physical component summary scores (35.8 and 43.2) and utility (0.68 and 0.74) and similar mental component summary scores (49.1 and 50.4); after multivariable adjustment, apparent treatment-resistant hypertension was associated with a 2.37 lower physical component summary score and a 0.02 lower utility. People living with hypertension told ICER that pill burden and additive copays for multiple medications can decrease adherence and persistence, and that insurance coverage barriers such as prior authorization and step therapy can cause people to abandon treatment.

Hypertension was associated with $2,759 in health care expenditures per person in the United States in 2019 and with estimated annual national health care expenditures of about $219.2 billion, including $32.5 billion in prescribed medication purchases. A review estimates that apparent resistant hypertension increases US health care expenditures by $11 billion to $18 billion per year over those associated with non-resistant hypertension. In linked US electronic medical record and claims data for 3,966 individuals with stage 3 to 4 chronic kidney disease using ≥3 antihypertensive medications, uncontrolled blood pressure (2,479 individuals) compared with controlled blood pressure (1,487 individuals) was associated with a higher risk of end-stage renal disease (HR 1.85) and inpatient hospitalization (rate ratio 1.35) and with higher total medical and pharmacy costs (mean difference $10,055 per patient per year). Out-of-pocket payments accounted for 16.6% of the $35.57 billion spent in the United States on treatment of hypertension in 2019, and in the 2017 National Health Interview Survey, 10.7% of 7,498 adults with self-reported hypertension reported cost-related medication nonadherence.

Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, and use rose from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that the rate of screening for primary aldosteronism in guideline-recommended individuals is <2% in the United States; among 269,010 Veterans with apparent treatment-resistant hypertension from 2000 to 2017, 4277 (1.6%) were tested for primary aldosteronism. A meta-analysis of 24 studies in people with uncontrolled blood pressure despite three or more antihypertensive medications of different classes estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%), and among 1348 participants in the UK and the Czech Republic, each additional antihypertensive medication was associated with an 85% and a 77% increase in biochemically confirmed nonadherence, respectively. With the aldosterone synthase inhibitor baxdrostat, hyperkalemia led to treatment discontinuation in 5.7% of participants in the pooled baxdrostat arm of the BaxHTN long-term extension, with safety data to 54 weeks.

Lorundrostat efficacy and safety

Summary: regulatory status and pivotal phase 3 trial Launch-HTN

Lorundrostat (MLS-101, formerly MT-4129) is an investigational oral aldosterone synthase inhibitor developed by Mineralys Therapeutics under an exclusive, worldwide license from Tanabe. Mineralys submitted a New Drug Application to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”, and the FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026; the company described the application as under review in November 2026. According to the company, the application includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial.

Launch-HTN (NCT06153693) was a phase 3, randomized, double-blind, placebo-controlled trial in adults with uncontrolled hypertension, including treatment-resistant hypertension, taking 2 to 5 antihypertensive medications, conducted at 159 sites in 13 countries (the registry lists 184 locations). Of 1,083 participants randomized in a 1:2:1 ratio, 1,078 received at least 1 dose: lorundrostat 50 mg for 6 weeks with possible escalation to 100 mg for 6 weeks (n = 270), lorundrostat 50 mg for 12 weeks (n = 538), or placebo (n = 270). For the primary endpoint, change in office systolic blood pressure at week 6 in the pooled 50 mg groups (n = 808) compared with placebo (n = 270), the least-squares mean change was −16.9 mm Hg (95% CI, −19.0 to −14.9) with lorundrostat and −7.9 mm Hg (95% CI, −11.5 to −4.2) with placebo, a difference of −9.1 mm Hg (95% CI, −13.3 to −4.9; P < .001); the March 2025 topline announcement states that the trial met its primary endpoint and gives the P value as < 0.0001. An office systolic blood pressure below 130 mm Hg at week 6 was achieved by 44.1% of participants receiving lorundrostat and 24.1% receiving placebo (odds ratio, 3.4; 95% CI, 1.5 to 7.8; P = .003), and the placebo-adjusted change at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9) in participants taking 2 antihypertensive medications and −9.0 mm Hg (97.5% CI, −14.0 to −4.1) in those taking 3 or more (P < .001 for both).

At week 12, the placebo-adjusted change in the 50 mg group, a prespecified exploratory outcome, was −11.6 mm Hg (95% CI, −16.3 to −7.0; P < .001) in the publication; the topline announcement gives 11.7 mm Hg. In the escalation group, 92 of 270 participants (34.1%) were escalated to 100 mg, the placebo-adjusted change at week 12 was −8.4 mm Hg (95% CI, −13.6 to −3.2; P = .002), and the investigators state that the higher dose “provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose”. In a secondary responder analysis of 790 participants with baseline office systolic blood pressure of 130 mm Hg or higher, 46.3% of the lorundrostat 50 mg group and 19.9% of the placebo group were below 130 mm Hg at week 12 (odds ratio, 3.86; 95% CI, 2.66-5.60). Treatment-emergent adverse events occurred in 538 of 1,078 participants (49.9%) and were mostly mild or moderate; serious adverse events occurred in 22 participants, 1 of them considered related to treatment, and 1 participant in the placebo group died (unrelated to treatment).

Summary: pivotal phase 2 trial Advance-HTN

Advance-HTN (NCT05769608) was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, described in the trial presentation as a “Phase 2b trial”, at 103 sites in the United States (the registry lists 104 locations). Participants taking 2 to 5 antihypertensive medications with an office blood pressure of 140/90 mm Hg or higher were switched for 3 weeks to a standardized regimen of indapamide 2.5 mg or hydrochlorothiazide 25 mg with olmesartan 40 mg, with amlodipine 10 mg added for those previously taking 3 to 5 medications, and those with a 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were randomized. Of 926 participants who started the standardized regimen, 285 were randomized for 12 weeks: 94 to lorundrostat 50 mg daily (stable dose), 96 to lorundrostat 50 mg with an increase to 100 mg if systolic blood pressure was 130 mm Hg or higher after 4 weeks (dose adjustment), and 95 to placebo. The mean age was 60 years, and 150 participants (53%) were Black.

For the primary endpoint, change in 24-hour average systolic blood pressure from baseline to week 12, the least-squares mean change was −15.4 mm Hg with the stable dose, −13.9 mm Hg with dose adjustment, and −7.4 mm Hg with placebo; the placebo-adjusted changes were −7.9 mm Hg (97.5% CI, −13.3 to −2.6) and −6.5 mm Hg (97.5% CI, −11.8 to −1.2), with P values of 0.001 and 0.006 in the presentation. At week 4, the placebo-adjusted change in the combined lorundrostat groups (n = 188) was −5.3 mm Hg (95% CI, −8.4 to −2.3; P < 0.001), and 41% of participants receiving lorundrostat and 18% receiving placebo had a 24-hour average systolic blood pressure below 125 mm Hg (odds ratio, 3.3 [1.4 to 7.8]; P < 0.001). By standardized regimen, the week 4 placebo-adjusted change was −6.1 mm Hg (−10.8 to −1.4; P = 0.001) with 2 medications and −4.6 mm Hg (−10.6 to 1.5; P = 0.060) with 3. In the 19 participants escalated to 100 mg, office systolic blood pressure changed by −17.5 mm Hg (−30.3 to −4.7; P < 0.001) from baseline to week 12, and the presenters concluded that escalation from 50 to 100 mg “did not lower blood pressure more than 50 mg and was associated with numerically more adverse events”.

Serious adverse events occurred in 6 participants (6.4%) receiving the stable dose, 8 (8.4%) receiving dose adjustment, and 2 (2.1%) receiving placebo according to the annual report (6%, 8%, and 2% in the presentation), and were considered treatment related in 2%, 1%, and 0%. Hypotension was reported in 9%, 8%, and 3%, and hyponatremia in 9%, 11%, and 6% of the stable-dose, dose-adjustment, and placebo groups. A potassium level above 6.0 mmol/L occurred in 5 participants (5%) with the stable dose, 7 (7%) with dose adjustment, and none with placebo in the publication abstract; the annual report gives 5.3% and 7.4% at scheduled visits and 2.1% and 3.2% after exclusion of spurious results.

Summary: long-term open-label extension Transform-HTN

Transform-HTN (NCT05968430) is a phase 3, single-group, open-label extension for participants who completed Launch-HTN, Advance-HTN, or Explore-CKD, with 1,076 participants enrolled; the registry describes a 52-week open-label treatment period, a double-blind randomized treatment withdrawal substudy, and a status of “Active, not recruiting”. The results reported in November 2026 cover the Launch-HTN cohort: of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled and received an additional 36 weeks of open-label lorundrostat, starting at 50 mg once daily (25 mg after a dose reduction in the parent trial) while continuing their existing antihypertensive medications. Of the 632, 549 (87%) completed treatment and 583 (92%) completed follow-up at week 48. The efficacy analysis (n = 504) excluded participants randomized to placebo in the 4-week withdrawal substudy.

The primary endpoint in the presentation, change in office systolic blood pressure from the Launch-HTN baseline to week 48 (the registry measure is stated at extension week 36), was −17.8 mmHg (95% CI, −19.6 to −16.0; P < 0.0001), a within-group change with no concurrent control group. At week 48, 56.0% of participants had an office systolic blood pressure below 130 mmHg (55.2% of those taking 2 antihypertensive drugs and 56.5% of those taking 3 or more), and serum aldosterone had decreased by 54.8% and plasma renin activity increased by 123.9% from baseline (not prespecified). No result was located for the randomized treatment withdrawal substudy, a registered primary outcome, or for participants who entered from Advance-HTN or Explore-CKD; the registry record states “No Results Posted”.

In the safety population (n = 632) during the 36-week open-label period, 413 participants (65.3%) had a treatment-emergent adverse event and 27 (4.3%) a serious adverse event, 2 (0.3%) of which investigators considered treatment related; no deaths occurred. Thirty-seven participants (5.9%) discontinued lorundrostat because of an adverse event, 10 (1.6%) of them for hyperkalemia. Hyperkalemia requiring trial drug modification occurred in 32 participants (5.1%), hyponatremia requiring trial drug modification in 28 (4.4%), symptomatic hypotension in 13 (2.1%), and serum potassium above 6.0 mmol/L confirmed by repeat testing in 16 (2.5%). The company states that serum potassium increased and eGFR decreased early in treatment and that “both remained stable through the open-label period to Week 48”.

Summary: phase 2 trials Target-HTN, Explore-CKD, and Explore-OSA

Target-HTN (NCT05001945) was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging trial at 43 sites in the United States (the registry lists 44 locations) in adults with a systolic automated office blood pressure of 130 mm Hg or greater while taking 2 or more antihypertensive medications. Of 200 participants randomized, 163 with suppressed plasma renin (cohort 1) were assigned in a 1:1:1:1:1:1 ratio to placebo or lorundrostat 12.5, 50, or 100 mg once daily or 12.5 or 25 mg twice daily, and 37 with plasma renin activity above 1.0 ng/mL/h (cohort 2) were assigned in a 1:6 ratio to placebo or 100 mg once daily, for 8 weeks; randomization to the two 12.5 mg regimens stopped after an interim analysis. For the primary endpoint, change in systolic automated office blood pressure at week 8, the placebo group changed by −4.1 mm Hg, and the placebo-subtracted changes with once-daily doses were −1.5 mm Hg (90% CI, −8.3 to 5.3; P = .71) for 12.5 mg, −9.6 mm Hg (90% CI, −15.8 to −3.4; P = .01) for 50 mg, and −7.8 mm Hg (90% CI, −14.1 to −1.5; P = .04) for 100 mg, with no adjustment for multiplicity; the 2022 topline announcement gives these reductions as 1.4 mmHg, 9.7 mmHg (p=0.010), and 7.9 mmHg (p=0.037). Of the 200 participants, 110 (55%) had an adverse event; 3 serious adverse events occurred, 1 deemed treatment related (worsening hyponatremia with 100 mg in cohort 2 that required stopping the drug), and no adrenocortical insufficiency occurred.

Explore-CKD (NCT06150924) was a phase 2, randomized, double-blind, placebo-controlled, 2-period, 2-sequence crossover trial at 42 sites in the United States in participants with uncontrolled hypertension and chronic kidney disease (eGFR of 30 mL/min/1.73 m2 or higher) with albuminuria who were receiving an ACE inhibitor or ARB and an SGLT2 inhibitor. The publication reports 59 participants randomized (registry enrollment, 60) to lorundrostat 25 mg once daily and placebo in 4-week treatment periods separated by a 4-week washout. For the primary endpoint, the least-squares mean change in automated office systolic blood pressure was −9.3 mm Hg with lorundrostat and −1.8 mm Hg with placebo (placebo-adjusted change −7.5 mm Hg; 95% CI, −12.3 to −2.7; P = 0.0024), and in an exploratory analysis the placebo-adjusted change in spot UACR was −25.6% (P = 0.0015). At least 1 treatment-emergent adverse event was reported by 29 of 58 participants during lorundrostat treatment (50%) and 19 of 57 during placebo treatment (33%), serious adverse events by 2 (3.4%) and 0, and 2 participants discontinued treatment because of adverse events attributed to lorundrostat (hyperkalemia with acute kidney injury, and worsening CKD).

Explore-OSA (NCT06785454) was a phase 2, randomized, double-blind, placebo-controlled crossover trial in participants with a body mass index of 27 kg/m2 or higher, an apnea-hypopnea index of 15 events/hour or higher, and hypertension, who received lorundrostat 50 mg once daily in the evening and placebo for 4 weeks each, separated by a 2-week washout; the congress abstract describes 47 participants, and the registry and the company's NDA acceptance release describe 48. For the primary endpoint, change in apnea-hypopnea index, there was “no difference in AHI response between lorundrostat- and placebo-treated participants”. For the key secondary endpoint, office systolic blood pressure, the abstract reports a placebo-adjusted reduction of 10.1 mmHg (P=0.0089) in the preplanned parallel-arm analysis of the first treatment period and 6.2 mmHg (P<0.0003) in the crossover analysis of both periods; the company release reports the first-period result as within-group reductions of 11.1 mmHg (p < 0.0001) with lorundrostat and 1.0 mmHg (p = NS) with placebo. No serious adverse events were reported, and the company release states that no serum potassium value exceeded 5.5 mmol/L.

Summary: phase 1 and clinical pharmacology

The first-in-human study MT-4129-E01 (NCT02953132) was a four-part, randomized, double-blind, placebo-controlled study at a single center in the Netherlands from November 2016 to May 2017. Of 245 participants screened, 116 healthy white participants were randomized: 64 men received a single dose of 5 to 800 mg or placebo in the fasted state, 36 men received 40, 120, or 360 mg or placebo once daily for 7 days in the fed state, and in one cohort of 8 women (part 3) and one cohort of 8 men aged 65 years or older (part 4), 6 participants each received a single 100 mg dose and 2 received placebo. After single doses, the median Tmax was 1.0 to 1.5 hours and the mean terminal half-life 7.9 to 10.5 hours; with multiple dosing, steady state was reached by about day 5, the mean accumulation ratio for AUC0–24 was 1.15 to 1.19, the mean half-life on day 7 was 9.1 to 11.9 hours, and 2.3% to 2.6% of the dose was excreted unchanged in urine. Exposure did not differ significantly between women and men or between older and younger adults. The capsule used in this study gives about 50% of the exposure of the tablet used in the phase 2 study.

In vitro, lorundrostat inhibited CYP11B2 with 374-fold selectivity over CYP11B1. Single doses of 10 to 800 mg reduced the plasma aldosterone AUC0–24 by 36% to 77% compared with placebo without affecting cortisol, multiple doses completely blunted the ACTH-stimulated aldosterone response with no effect on the cortisol response, and plasma aldosterone rebounded by 73% to 163% compared with placebo from 24 hours after the last dose. The authors state that dose selection for hypertension “should avoid the higher dose level and focus on doses up to 120 mg daily”. No serious treatment-emergent adverse events occurred; treatment-emergent adverse events were reported in 41 of 87 participants receiving lorundrostat (47%) and 18 of 29 receiving placebo (62%), mild dizziness in 9 (10.3%) and 1 (3.4%), and one participant was withdrawn after a single 360 mg dose because of sinus tachycardia. Within 2 days of multiple dosing, serum potassium rose by group means of 0.28 to 0.38 mmol/L, and no participant reached the stopping criterion of 6.0 mmol/L. In a concentration-QTc analysis of the same study, a placebo-corrected QTcF effect above 10 ms was excluded at plasma concentrations up to about 7800 ng/mL, 4.8-fold the predicted Cmax at 100 mg once daily, and the regulatory requirement for a thorough QT study was waived.

Summary: hyperkalemia, hyponatremia, and eGFR across trials

No integrated safety analysis across trials was located; the figures below come from the individual trials, and hyperkalemia rates depend on whether a single value or a value confirmed by repeat testing is counted. In Launch-HTN, serum potassium above 6.0 mmol/L occurred in 4 participants (1.5%) in the escalation group, 6 (1.1%) in the 50 mg group, and 2 (0.7%) in the placebo group; after exclusion of spurious results, the annual report gives confirmed hyperkalemia of 1.1% and 0.6% in the two lorundrostat groups. Hyperkalemia requiring trial drug modification occurred in 7 (2.6%), 11 (2.0%), and 1 (0.4%) Launch-HTN participants, and 1 (0.37%) and 2 (0.37%) in the two lorundrostat groups discontinued for hyperkalemia. In Advance-HTN, potassium above 6.0 mmol/L occurred in 5% and 7% of the two lorundrostat groups and none of the placebo group in the publication abstract (5.3% and 7.4% in the annual report), and in 2.1% and 3.2% after confirmation. In Target-HTN, 6 participants (3.6%) had potassium above 6.0 mmol/L. In Explore-CKD, hyperkalemia was reported in 15.5% of participants during lorundrostat treatment and 3.5% during placebo, 3 participants (5.2%) had confirmed potassium above 6.0 mmol/L, and 5 (8.6%) had a dose modification for hyperkalemia. In Explore-OSA, no potassium value exceeded 5.5 mmol/L, and in the Transform-HTN extension 16 participants (2.5%) had confirmed potassium above 6.0 mmol/L and 10 (1.6%) discontinued for hyperkalemia.

In Launch-HTN, hyponatremia requiring trial drug modification occurred in 28 (10.4%), 37 (6.9%), and 9 (3.3%) participants in the escalation, 50 mg, and placebo groups, serum sodium below 125 mmol/L in 4 (1.5%), 4 (0.7%), and 1 (0.4%), and 1 (0.37%) and 2 (0.37%) lorundrostat-treated participants discontinued for hyponatremia. Hyponatremia was reported in 9% and 11% of the two Advance-HTN lorundrostat groups and 6% of the placebo group, in 5.2% of participants during lorundrostat treatment and 5.3% during placebo in Explore-CKD (with no serum sodium value below 125 mmol/L), and as requiring trial drug modification in 28 (4.4%) Transform-HTN participants. In Target-HTN, the 1 treatment-related serious adverse event was worsening hyponatremia that required stopping the drug.

In Launch-HTN, creatinine-based eGFR decreased by 9.3% from baseline to week 12 in both lorundrostat groups and increased by 0.4% with placebo, and cystatin C-based eGFR decreased by 5.2% and 4.1% and increased by 3.4% with placebo; the investigators describe the decline as expected and use the cystatin C equation to correct for creatinine elevation caused by competition between lorundrostat and creatinine for MATE1-dependent transport. Reduction in eGFR requiring trial drug modification occurred in 9 (3.3%), 16 (3.0%), and 2 (0.7%) Launch-HTN participants, and 3 (0.56%) in the 50 mg group discontinued for it. In Explore-CKD, the placebo-adjusted change was −1.97 mL/min/1.73 m2 (95% CI, −3.83 to −0.11; P = 0.0380) in cystatin C-estimated eGFR and −6.09 mL/min/1.73 m2 (95% CI, −8.12 to −4.05; P < 0.0001) in creatinine-estimated eGFR; 9 participants had a cystatin C eGFR decrease of 25% or more, none had a decrease of 50% or more, and 6 (10.3%) had a dose modification for reduced kidney function. In Transform-HTN, the company reports that eGFR decreased early in treatment and remained stable through week 48.

Budget impact of Lorundrostat

Summary: price status, comparator costs, and costs of uncontrolled hypertension

Lorundrostat has no announced price. On its third quarter 2026 earnings call, Mineralys stated that “we haven't finalized the price yet” and that it would communicate pricing, access, and gross to net information “sometime post approval, post launch”. On its fourth quarter 2025 earnings call, the company described its pricing frame as “more of an SGLT2-branded price point, Entresto price point, broadly at a WAC” and stated that it had “not guided as it relates to rebates”. No estimate of monthly and annual cost is given, because lorundrostat is not approved and no price has been published.

The Institute for Clinical and Economic Review (ICER) costed lorundrostat 50 mg once daily at a placeholder price equal to the baxdrostat wholesale acquisition cost (WAC) from RedBook ($900 for 30 tablets), or $30 per dose and $10,950 per year; for baxdrostat, ICER used the WAC as the net price because no information was available to inform a discount. For the generic comparators, ICER used the median WAC across generic versions: $43 to $171 per year for spironolactone (25 to 100 mg), $511 to $1,022 per year for eplerenone (50 to 100 mg), and $206 to $411 per year for amiloride (5 to 10 mg). The National Average Drug Acquisition Cost (NADAC) effective 18 November 2026 was $28.78424 per BAXFENDY 2 mg tablet, $0.04218 per spironolactone 25 mg tablet, $0.47438 per eplerenone 50 mg tablet, and $0.20688 per amiloride 5 mg tablet.

In a US claims cohort of 3,966 individuals with stage 3 to 4 chronic kidney disease using three or more antihypertensive drugs, uncontrolled blood pressure was associated with $10,055 higher total medical and pharmacy costs per patient per year than controlled blood pressure. A review estimates that apparent resistant hypertension increases US health care expenditures by $11 billion to $18 billion per year over non-resistant hypertension. ICER's model applied annual health state costs of $3,211 for hypertension and $108,953 for end-stage kidney disease.

Summary: ICER cost-effectiveness and health-benefit price benchmark

ICER assessed baxdrostat and lorundrostat in a 2026 evidence report discussed at the “Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension”. The assessment page lists a “Final Evidence Report and Meeting Summary”, and the meeting slides state that the final report would be published “on or around November 30, 2026”; the figures below are from the evidence report. ICER rated the evidence “insufficient” to distinguish the net health benefits of lorundrostat and baxdrostat, rated either drug “Promising but Inconclusive” compared with spironolactone, eplerenone, or amiloride in Population 1 (resistant hypertension not at goal) and Population 2 (not at goal on two drugs after not tolerating a third), and rated either drug “comparable or inferior” to amlodipine in Population 3.

ICER's de novo model took a US health care sector perspective over a lifetime horizon, with costs and outcomes discounted at 3% per year and three-month cycles. Populations 1 and 2 were modeled as one population, and Population 3 was not modeled. Lorundrostat was modeled at 50 mg once daily and at the placeholder price of $10,950 per year. Lifetime total costs were $150,700 with lorundrostat against $122,800 with spironolactone, $124,300 with eplerenone, and $123,400 with amiloride, with 9.54 QALYs against 9.52, 9.54, and 9.52. The incremental cost-effectiveness ratio for lorundrostat was $1,419,000 per QALY gained compared with spironolactone and $1,492,000 per QALY gained compared with amiloride. Compared with eplerenone, lorundrostat was “More costly, less effective”, which ICER attributed to a first-cycle discontinuation probability of 10% for lorundrostat (from Launch-HTN) against 7.7% for eplerenone. Baxdrostat at its WAC had ratios of $833,000, $2,077,000, and $851,000 per QALY gained compared with spironolactone, eplerenone, and amiloride. In probabilistic analyses, lorundrostat was cost-effective in 0.0% of simulations at $150,000 per evLY gained against each comparator and in 0.2% at $200,000 per evLY gained against eplerenone and amiloride. In the modified societal perspective scenario, its ratios were $1,404,000 per QALY gained compared with spironolactone and $1,479,000 compared with amiloride, and ICER stated that the ratios in the modified societal and same-discontinuation scenarios were “still well above commonly accepted threshold ranges”.

The health-benefit price benchmark, the price range that achieves $100,000 per QALY gained to $150,000 per evLY gained, was $760 to $1,600 per year for lorundrostat, a discount from the placeholder price of 86.3% to 93.0% on the QALY basis and 85.7% to 93.0% on the evLY basis, and $1,400 to $2,500 per year for baxdrostat.

In public comments, Mineralys stated that the model “does not fully capture the clinical and economic benefits of ASIs”, recommended removing amiloride and eplerenone as comparators, noted that the 7.7% discontinuation rate for eplerenone and amiloride came from a study of Swedish patients receiving calcium channel blockers, and recommended dynamic pricing. ICER responded that it tested several discontinuation scenarios and “none changed our conclusion”, and that it does not as a rule consider dynamic pricing without known timing for patent expiry. The coalition No Patient Left Behind estimated a societal value-based price for lorundrostat of $18,767 per year (base case) to $26,913 per year (optimistic case).

Summary: ICER potential budget impact, other economic evaluations, and forecasts

ICER's potential budget impact analysis is the only budget impact analysis of lorundrostat identified. It calculated health care costs, including drug costs, minus offsets from averted health care events, undiscounted over five years, against an even split of spironolactone, eplerenone, and amiloride, with 20% uptake in each year. Population 1 was sized from a hypertension prevalence of 48.1% among US adults, 51.2% of those with hypertension taking medication, and 15% of those taking medication treated with three or more drugs and uncontrolled, applied to 271,862,765 adults: 10,042,828 eligible patients, or 2,008,565 initiating treatment per year. Population 2 (17.9% treated with two drugs and uncontrolled, of whom 21% were assumed, as a “placeholder estimate”, to have tried and discontinued a third) comprised 2,516,732 patients, or 503,346 per year, for a total of 12,559,560 eligible patients. ICER did not estimate the budget impact for Population 3. At the placeholder price of $10,950 per year, the cumulative budget impact per patient was approximately $8,500 in year one and $16,300 by year five (baxdrostat: $8,300 and $15,700), and approximately 2% of eligible patients could be treated before reaching ICER's potential budget impact threshold of $821 million per year. At threshold prices, 100% of eligible patients could be treated compared with eplerenone at every threshold, and compared with spironolactone ($630) and amiloride ($810) at $50,000 per evLY gained; at $200,000 per evLY gained, approximately 17% (spironolactone, $1,800) and 15% (amiloride, $1,900) could be treated. ICER reports national figures; a 2026 poster hosted by Mineralys estimates, for a hypothetical 1 million–member US health plan, 194,140 adults diagnosed and treated for hypertension, 104,494 (53.8%) with uncontrolled hypertension, and 37,081 receiving three or more antihypertensive drugs. Mineralys describes its initial target population as “third line or later”.

No published cost-effectiveness analysis of lorundrostat other than ICER's was identified, and a 2026 review states that aldosterone synthase inhibitors need “evidence of cost-effectiveness”. No published cost-effectiveness analysis of spironolactone, eplerenone, amiloride, or aprocitentan for resistant hypertension was identified. A 2026 systematic review found 21 modelling studies in treatment-resistant and uncontrolled hypertension, and 12 of its 14 cost-utility analyses evaluated renal denervation. Published analyses report $32,732 per QALY for radiofrequency renal denervation (Medicare payer perspective, lifetime horizon), $12,900 per QALY for ultrasound renal denervation (US health care system perspective, lifetime horizon, procedure cost $23,000), $3,071 per QALY in a 2012 societal-perspective model in resistant hypertension, $4,400 per QALY gained for team-based care with non-physician medication titration at 10 years, and cost savings of $10,162 per person for pharmacist prescribing.

GlobalData forecast lorundrostat sales of $601 million in 2030. Visible Alpha consensus assigns lorundrostat a 90% probability of US approval, with risk-adjusted sales of $122 million in 2027 and $365 million in 2028, and projects higher sales for baxdrostat than for lorundrostat over the remainder of the decade; the same report states that analysts expect annual revenue of $1.1 billion by 2030.

Conclusions

Summary

Lorundrostat is an investigational oral aldosterone synthase inhibitor developed by Mineralys Therapeutics. Mineralys submitted a New Drug Application to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”, and the application is under review with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. No prescribing information, approved dose, or price is available; on its third quarter 2026 earnings call, the company stated that “we haven't finalized the price yet”. Baxdrostat (BAXFENDY, AstraZeneca), an aldosterone synthase inhibitor, was approved by the FDA on May 15, 2026 for the treatment of hypertension in combination with other antihypertensive drugs in adults who are not adequately controlled on other agents, and lorundrostat would be the second approved drug of the class.

The efficacy evidence comes from two placebo-controlled trials that the company describes as pivotal, both in adults with uncontrolled hypertension taking 2 to 5 antihypertensive medications. In the phase 3 Launch-HTN trial (1,083 participants randomized, including participants with treatment-resistant hypertension), lorundrostat 50 mg daily added to existing therapy changed automated office systolic blood pressure at week 6 by −16.9 mm Hg against −7.9 mm Hg with placebo, a difference of −9.1 mm Hg (95% CI, −13.3 to −4.9; P < .001), and 44.1% of participants receiving lorundrostat and 24.1% receiving placebo reached an office systolic blood pressure below 130 mm Hg; the placebo-adjusted change at week 12 in the 50 mg group, an exploratory outcome, was −11.6 mm Hg. In the phase 2 Advance-HTN trial (285 participants randomized after a switch to a standardized background regimen), the placebo-adjusted change in 24-hour ambulatory systolic blood pressure at week 12 was −7.9 mm Hg with lorundrostat 50 mg and −6.5 mm Hg with a 50 to 100 mg dose-adjustment strategy. In both trials, escalation from 50 mg to 100 mg gave no additional reduction in blood pressure. In Explore-CKD, 59 participants with chronic kidney disease and albuminuria were randomized, and lorundrostat 25 mg changed automated office systolic blood pressure by −7.5 mm Hg relative to placebo over a 4-week crossover period.

Placebo-controlled data extend to 12 weeks. In the Transform-HTN open-label extension, 632 of the 808 Launch-HTN participants who received lorundrostat (78%) enrolled; the change in office systolic blood pressure from the Launch-HTN baseline to week 48 was −17.8 mmHg (95% CI, −19.6 to −16.0), a within-group change with no concurrent control group, and 56.0% of participants had an office systolic blood pressure below 130 mmHg at week 48. These results are available as congress slides and a company press release.

Hyperkalemia, hyponatremia, and an early decrease in eGFR were the adverse events of special interest across trials. In Launch-HTN, serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, and hyperkalemia requiring trial drug modification in 2.6% and 2.0% against 0.4%. In Advance-HTN, potassium above 6.0 mmol/L occurred in 5% and 7% of the two lorundrostat groups and no placebo participants (2.1% and 3.2% after confirmation by repeat testing); in Explore-CKD, hyperkalemia was reported in 15.5% of participants during lorundrostat treatment and 3.5% during placebo; and in Transform-HTN, 2.5% of participants had potassium above 6.0 mmol/L confirmed by repeat testing and 1.6% discontinued lorundrostat for hyperkalemia. Hyponatremia requiring trial drug modification occurred in 10.4% and 6.9% of the Launch-HTN lorundrostat groups and 3.3% of the placebo group, and hyponatremia was reported in 9% and 11% of the Advance-HTN lorundrostat groups and 6% of the placebo group. In Launch-HTN, creatinine-based eGFR decreased by 9.3% from baseline to week 12 with lorundrostat and increased by 0.4% with placebo (cystatin C-based eGFR, decreases of 5.2% and 4.1% against an increase of 3.4%), and the company states that serum potassium increased and eGFR decreased early in treatment and that “both remained stable through the open-label period to Week 48”. Launch-HTN excluded people with an eGFR below 45 mL/min/1.73 m2 or serum potassium above 5.0 mmol/L at screening. The BAXFENDY label directs assessment of serum potassium and serum sodium before initiation and periodically thereafter.

No trial of lorundrostat has measured cardiovascular, kidney, or mortality outcomes, and the BAXFENDY label states for baxdrostat that “There are no controlled trials demonstrating risk reduction of these events”. No head-to-head trial has compared lorundrostat with spironolactone, baxdrostat, or another add-on drug; in a network meta-analysis of 10 trials with 2,865 participants, the mean differences in office systolic blood pressure against placebo were −6.80 mmHg for lorundrostat, −9.09 mmHg for baxdrostat, and −10.78 mmHg for spironolactone. No results were located for the Transform-HTN randomized treatment withdrawal substudy, a registered primary outcome, and the registry record states “No Results Posted”. ICER's evidence report rated the evidence “insufficient” to determine the net health benefits of lorundrostat and baxdrostat compared with each other in all three of its populations, rated either drug “Promising but Inconclusive” compared with spironolactone, eplerenone, or amiloride in Populations 1 and 2, and rated either drug “comparable or inferior” to amlodipine in Population 3. With lorundrostat costed at a placeholder price of $10,950 per year equal to the baxdrostat wholesale acquisition cost, ICER estimated $1,419,000 per QALY gained compared with spironolactone and a health-benefit price benchmark of $760 to $1,600 per year. ICER's final report is scheduled for publication “on or around November 30, 2026”.